MINIMALLY INVASIVE LUNG ADENOCARCINOMA
Clinical trials for MINIMALLY INVASIVE LUNG ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new MINIMALLY INVASIVE LUNG ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for MINIMALLY INVASIVE LUNG ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Major trial aims to tame dozens of rare, neglected cancers with immune power combo
Disease control OngoingThis study is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control many different types of rare, advanced cancers that have limited treatment options. It enrolled over 800 adults whose cancer progressed after standard therapy. The g…
Matched conditions: MINIMALLY INVASIVE LUNG ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 04, 2026 05:06 UTC
-
New drug boosts standard treatment in fight against advanced lung cancer
Disease control OngoingThis study is testing if adding an experimental drug called veliparib to standard chemotherapy and radiation is more effective for people with stage III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if the combination helps patients live longer …
Matched conditions: MINIMALLY INVASIVE LUNG ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:54 UTC
-
Can a One-Two punch of radiation and immune therapy better fight lung cancer?
Disease control OngoingThis study is testing if combining a targeted, high-dose radiation treatment with an immunotherapy drug works better than radiation alone for certain early-stage or recurrent non-small cell lung cancers. About 140 participants will be randomly assigned to receive either the radia…
Matched conditions: MINIMALLY INVASIVE LUNG ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC